Target intelligence / Profile preview

Enterobacteriaceae fimbrial adhesin

Molecular classification
Other (fimbrial/adhesin), Surface adhesion protein, Bacterial adhesin
01

Overview

Enterobacteriaceae fimbrial adhesins are a family of surface proteins expressed by Gram-negative bacteria, notably Escherichia coli, Klebsiella pneumoniae, and Salmonella spp., that mediate adhesive attachment to host cells[1][2][3][4]. The canonical member is the FimH adhesin, which resides at the tip of type 1 fimbriae (pili). FimH recognizes and binds to terminal mannose residues on host glycoproteins, enabling bacterial colonization, especially in the urinary tract[1][2]. The adhesin operates through a shear-dependent, allosteric catch-bond mechanism in which binding affinity increases under mechanical force, helping bacteria resist wash-off in the urinary tract[1][4]. Type 1 fimbriae are essential for initial stages of infection, including adherence to uroepithelial cells, thus playing a central role in urinary tract infections[1][2]. Diversity among FimH variants and fimbrial shaft compositions modulates tissue specificity and binding strength, which has implications for bacterial pathogenesis and host specificity[1][2][6]. Note: - "Enterobacteriaceae fimbrial adhesins" is a plural/generic term referring to a class of adhesins, not a single molecular target. The most studied and therapeutically relevant is "FimH adhesin," and structured information should refer to this canonical form when possible[1][4][6]. - No standard abbreviation for the plural term; "FimH" is widely used for the gene/protein. - Not a classic drug target in existing therapeutics, but an active field of anti-adhesion drug and vaccine research targeting FimH or analogous adhesins[1]. Summary of structure/function: - FimH consists of a mannose-binding lectin (N-terminal) domain and a pilin (C-terminal) domain[1][4]. - Mutations (such as S62A) can increase affinity and alter shear dependency, impacting pathogenic potential[1]. - Different fimbriae exist within Enterobacteriaceae, each with distinct but sometimes overlapping receptor specificity[2][3][6]. Reason for is_incorrect:true: - "Enterobacteriaceae fimbrial adhesins" is not a singular standardized target name but rather a family/class; scientific and therapeutic discussions focus on the specific adhesin (usually FimH adhesin)[1][4]. - For structured datasets, use the specific singular canonical name "FimH adhesin" or analogous protein from the bacterial species of interest.

Other names
Type 1 fimbrial adhesinFimH adhesinFimbrial adhesinType 1 pilus adhesinMannose-sensitive adhesin
02

Mechanism of action

Inhibition of fimbrial adhesion; competitive inhibition of the mannose-binding site; prevention of bacterial attachment to host cells

03

Biological functions

Bacterial adhesion to host cellsTissue tropism determinationColonization of host tissuesUrinary tract infection pathogenesisShear-dependent adhesion
04

Disease associations

InfectionBacterial pathogenesisUrinary tract infection
05

Safety considerations

Antigenic variationresistance through mutationincomplete specificity across bacterial strainschallenge in druggability as a surface adhesin
06

Interacting drugs

None established (investigational anti-adhesin compounds, vaccines, or inhibitors targeting FimH have been described but are not standard drugs)
07

Biomarkers

Presence of FimH or type 1 fimbriae on bacteria (for identification of uropathogenic strains)mannose-sensitive hemagglutination

Beyond the preview

Go deeper on Enterobacteriaceae fimbrial adhesin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterobacteriaceae fimbrial adhesin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call